REG - Creo Medical Group - Result of AGM
RNS Number : 9382QCreo Medical Group PLC24 June 2020Creo Medical Group plc
("Creo" or the "Company")
Result of Annual General Meeting
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that all resolutions put to shareholders at the Company's Annual General Meeting held earlier today were duly passed.
The voting results will be made available on the Investor Relations section of Company's website shortly: https://investors.creomedical.com/investors/reports-and-presentations/2020
Enquiries:
Creo Medical Group plc
Richard Rees (CFO)
+44 (0)1291 606 005
Cenkos Securities plc
+44 (0)20 7397 8900
Stephen Keys / Cameron MacRitchie (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd
Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Lianne Cawthorne
Mob: +44 (0)7980 541 893 / +44 (0)7515 909 238
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA Advanced Energy Platform powered by unique full spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, investors.creomedical.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDRAGUSUKRRSUNURR
Recent news on Creo Medical
See all newsREG - Creo Medical Group - Result of General Meeting & TVR
AnnouncementREG - Creo Medical Group - Result of Retail Offer
AnnouncementREG - Creo Medical Group - Extension of Retail Offer Closing Date
AnnouncementREG - Creo Medical Group - Result of Placing
AnnouncementREG - Creo Medical Group - Half-year Report
Announcement